A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Have unresectable, metastatic histologically- or cytologically-confirmed adenocarcinoma of the pancreas
Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Must consent to provide archived or recently obtained tumor tissue during Screening
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
You may not be if
Have prior systemic therapy, surgery, or radiation (except palliative radiation) in the unresectable, locally advanced or metastatic setting
Prior c-MET targeting therapy
History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan, including a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
Prior bone marrow transplant, solid organ transplant, or previous clinical diagnosis of tuberculosis.
Clareo Health | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
